Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
ImmuPharma ( (GB:IMM) ) has provided an announcement.
ImmuPharma has initiated IND-enabling activities for its Kapiglucagon program, a proprietary glucagon prodrug for Type 1 diabetes, after signing a work order with specialist consultancy tranScrip. The partner will help shape regulatory strategy and prepare for a pre-IND meeting with the FDA, supporting a planned 505(b)(2) pathway that could streamline U.S. development by leveraging existing glucagon data.
Kapiglucagon is designed to overcome native glucagon’s solubility and stability issues, enabling pump-compatible, dual-hormone artificial pancreas systems that could offer an alternative to insulin-only devices in a global insulin pump market forecast to reach $13.6bn by 2035. The company sees the asset as a key strategic opportunity alongside its lead candidate P140, with upcoming FDA interactions, IND filing and planned first-in-human studies intended to create value and position the program for future partnering in next-generation diabetes care.
Spark’s Take on IMM Stock
According to Spark, TipRanks’ AI Analyst, IMM is a Neutral.
The score is weighed down primarily by very weak financial performance (near-zero revenue, persistent losses, ongoing cash burn, and negative equity). Technicals are mixed but modestly supportive versus the 200-day average, while valuation remains challenged due to losses and the absence of dividend yield.
To see Spark’s full report on IMM stock, click here.
More about ImmuPharma
ImmuPharma PLC is a UK-based specialty biopharmaceutical company focused on discovering and developing peptide-based therapeutics. Its portfolio targets autoimmune diseases and anti-infective indications, and it is now expanding into diabetes care technologies through proprietary hormone-based drug candidates such as Kapiglucagon, with an eye on next-generation insulin pump and artificial pancreas markets.
Average Trading Volume: 3,015,648
Technical Sentiment Signal: Strong Sell
Current Market Cap: £25.83M
For an in-depth examination of IMM stock, go to TipRanks’ Overview page.